Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study.

ABSTRACT:

Objectives

Many patients with major depressive disorder must try multiple antidepressants before they identify a drug that is both effective and tolerable. Pharmacogenomic (PGx) testing may provide clinicians with guidance around medication choice based on a patient's drug response-related genetic variants. However, this technology is not routinely used in clinical care in Canada, and the views of key actors in the implementation process are largely unknown. The objective of this study was to qualitatively elicit the perspectives and attitudes of clinicians, scientists, policy actors and members of industry about PGx testing to guide antidepressant prescribing in primary care via interviews to help inform implementation policies for this technology.

Design

We conducted a qua

SUBMITTER: Cernat A 

PROVIDER: S-EPMC12406874 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature